Anti-parasitic Drugs Market to Record Sturdy Growth by 2025

The anti-parasitic drugs refers to that very particular type of medications that are meant for the purpose of treatment of various parasitic diseases, such as those caused by parasitic fungi, protozoa, helminths, ectoparasites, and amoeba amongst many others. Anti-parasitic drugs target and attack the parasitic agents of various infections and destroying them or restraining their growth and development. These drugs are generally effective and work well against a limited number of certain parasites within a very specific class of the parasites. Anti-parasitic drugs are one of those antimicrobial drugs that make an inclusion of antibiotics that target and destroy bacteria. They comprise those anti-fungals also which target and destroy fungi. These drugs could be administered topically, intravenously, and orally.

Some of the anti-parasitic drugs that are known for efficacy while treating a large range of infections brought forth by different classes of parasites are broad-spectrum antibiotics for bacteria, broad-spectrum anti-parasitic, and analogous.

It is believed that almost all of the general and common human body infections that are caused by parasitic worm infections can be treated and cured with any one of the five anthelmintics that are used presently, namely diethylcarbamazine, ivermectin, albendazole, praziquantel and mebendazole. The aim of anthelmintic treatment is to reduce the infection intensity under the scale of clinical importance.

Request to View Brochure of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=35858

There are many factors that are attributed with the increasing prevalence of the said drugs. Factors such as affordability of the drugs, surging occurrences of parasitic infections, ease of direct purchase, and so on stimulate the growth of the Anti-parasitic Drugs Market.

Anti-parasitic drugs are medications that are used for the treatment of parasitic diseases caused by parasites such as fungi and protozoa. These drugs destroy or inhibit the growth of parasitic agents by targeting them. In a particular class, these medications are effective to a limited number of parasites. Parasitic infections can be severe, moderate, or mild. Ascariasis is one of the prevalent parasitic diseases. Other common infections are hookworm disease, trichomoniasis, and toxoplasmosis. The parasitic infections can result in nutritional deficiencies, fetal or neonatal harm, cutaneous nodules, and skin eruptions. Moreover, the infections may cause major damages to the central nervous system, lungs, eyes, heart, and liver.

Anti-parasitic medications can be administered orally or intravenously, and these are one of the antimicrobial agents that include antibiotics that target bacteria. The World Health Organization (WHO) has suggested for public beneficial for the treatment of parasitic worm infections. Almost all of the common parasitic worm infections in the human body can be cured with one of five anthelmintics currently in use: mebendazole, albendazole, diethylcarbamazine, praziquantel, and ivermectin. The purpose of the anthelmintic treatment is to moderate the intensity of the infection beneath the level of clinical significance.

Request to View ToC of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=35858

Factors such as rising prevalence of parasitic infections, increasing novel drug treatment, affordability of drugs, convenience of direct purchase, high adoption and acceptance in developing markets, and innovations and developments of drugs are driving the growth of the global anti-parasitic drugs market. However, certain factors such as stiff competition among existing players, high possibilities of substance abuse and addiction, complications and severity involved in taking wrong medications due to misdiagnosis or incorrect self-diagnosis, and lack of awareness among the rural population in developing and underdeveloped economies could restraint the global market growth during the forecast period.

The global anti-parasitic drugs market is classified on the basis of drug, disease indication, distribution channel, and geography. In terms of drug, the market is classified into anthelmintics, scabicides and pediculicides, antiprotozoals, and others. The anthelmintics sub-segment is further segmented into benzimidazole, ivermectin, and pyrantel. The scabicides and pediculicides sub-segment is further classified into lindane, benzyl benzoate, and others. The antiprotozoals sub-segment is classified into chloroquine, pyrimethamine, and others. In terms of disease indication, the anti-parasitic drugs market is segmented into giardiasis, trichuriasis, filariasis, neurocysticercosis, hydatid disease, pinworm disease, cysticercosis, ascariasis, and others. The key distribution channels of the anti-parasitic drugs market include hospital pharmacies, retail pharmacies, online pharmacies, mail order pharmacies, and others.

Geographically, the anti-parasitic drugs market has been segmented into five major regions: North America (U.S. and Canada), Europe (Germany, France, the U.K., etc.), Asia Pacific (Australia, China, Japan, India, etc.), Latin America (Brazil, Mexico, etc.), and Middle East & Africa (GCC Countries, South Africa, etc.). North America is the leading market for anti-parasitic drugs in terms of revenue, followed by Europe. The U.S. holds the largest share of the North America market. Asia Pacific and Latin America are emerging markets which are expected to witness significant growth rates during the forecast period. High growth rates in these regions are attributable to the increasing incidence of parasitic infections, rising health care industries, and growing government investment to develop health care infrastructure. The anti-parasitic drugs market in countries such as China, India, and Brazil is projected to expand at a high growth rate during the forecast period due to increase in awareness among the population about parasitic infections and their treatment.

Major players operating in the global market for anti-parasitic drugs include Arbor Pharmaceuticals Inc., Quepharma, Merck & Co., Inc., Cipla, Inc., Ipca Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Guilin Pharmaceutical (Shanghai) Co., Ltd., Novartis AG, Mylan Labs, Ajanta Pharma, Sanofi, and AstraZeneca plc., Pfizer Inc., Bayer AG, GlaxoSmithKline, Alkem Laboratories Limited, Mankind Pharma, Indoco Remedies Ltd., Lincoln Pharmaceuticals Ltd., and Mallinckrodt Pharmaceuticals.

View Report -

https://www.transparencymarketresearch.com/antiparasitic-drugs-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.